PMID- 27075395
OWN - NLM
STAT- MEDLINE
DCOM- 20171116
LR  - 20210109
IS  - 2045-7634 (Electronic)
IS  - 2045-7634 (Linking)
VI  - 5
IP  - 7
DP  - 2016 Jul
TI  - Hepatitis B virus mutations, expression quantitative trait loci for PTPN12, and 
      their interactions in hepatocellular carcinoma.
PG  - 1687-93
LID - 10.1002/cam4.712 [doi]
AB  - Previously we identified that HBV(Hepatitis B virus) sequence variation, which 
      may interact with host human leukocyte antigen (HLA) genetic variation, could 
      influence host risk of hepatocellular carcinoma (HCC). More HBV-host interactions 
      need to be identified. Protein tyrosine phosphatase nonreceptor type 12 (PTPN12), 
      serves as an antagonist to tyrosine kinase signaling, may play integral roles in 
      immune response against HBV infection and the development of HCC. Rs11485985 was 
      an expression quantitative trait loci (eQTL) for PTPN12 by bioinformatics 
      analyses. In this study, we genotyped the PTPN12 eQTL and sequenced the HBV 
      region EnhII/BCP/PC in a case-control cohort including 1507 HBV-related HCC cases 
      and 1560 HBV persistent carriers as controls. The variant genotype GG of 
      rs11489585 increased HCC risk compared to the HBV persistent carriers (adjusted 
      OR = 2.03, 95% confidence interval [CIs] = 1.30-3.18). We also detected 
      borderline significant associations of PTPN12 eQTL rs11489585 with HBV mutations 
      (P = 0.05 for G1799C). Taken together, PTPN12 may influence HCC risk accompanied 
      by HBV mutations.
CI  - (c) 2016 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
FAU - Song, Ci
AU  - Song C
AD  - Department of Epidemiology, Collaborative Innovation Center For Cancer 
      Personalized Medicine, School of Public Health, Nanjing Medical University, 
      Nanjing, 211166, China.
AD  - Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative 
      Innovation Center of Cancer Medicine, Nanjing Medical University, Nanjing, 
      211166, China.
FAU - Liu, Yao
AU  - Liu Y
AD  - Pathology Center and Department of Pathology, Soochow University, Suzhou, China.
FAU - Xu, Lu
AU  - Xu L
AD  - Department of Epidemiology, Collaborative Innovation Center For Cancer 
      Personalized Medicine, School of Public Health, Nanjing Medical University, 
      Nanjing, 211166, China.
FAU - Wen, Juan
AU  - Wen J
AD  - Nanjing Maternity and Child Health Care Institute, Nanjing Maternity and Child 
      Health Care Hospital Affiliated with Nanjing Medical University, Nanjing, China.
FAU - Jiang, Deke
AU  - Jiang D
AD  - State Key Laboratory of Genetic Engineering, Collaborative Innovation Center for 
      Genetics and Development, School of Life Sciences, Fudan University, Shanghai, 
      China.
FAU - Chen, Jianguo
AU  - Chen J
AD  - Qidong Liver Cancer Institute, Qidong, China.
FAU - Zhai, Xiangjun
AU  - Zhai X
AD  - Department of Infection Diseases, Jiangsu Province Center for Disease Prevention 
      and Control, Nanjing, China.
FAU - Hu, Zhibin
AU  - Hu Z
AD  - Department of Epidemiology, Collaborative Innovation Center For Cancer 
      Personalized Medicine, School of Public Health, Nanjing Medical University, 
      Nanjing, 211166, China.
AD  - Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative 
      Innovation Center of Cancer Medicine, Nanjing Medical University, Nanjing, 
      211166, China.
FAU - Liu, Li
AU  - Liu L
AD  - Digestive Endoscopy Center, the First Affiliated Hospital of Nanjing Medical 
      University, Nanjing, China.
FAU - Liu, Jibin
AU  - Liu J
AD  - Department of Hepatobiliary Surgery, Nantong Tumor Hospital, Nantong, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20160414
PL  - United States
TA  - Cancer Med
JT  - Cancer medicine
JID - 101595310
RN  - EC 3.1.3.48 (PTPN12 protein, human)
RN  - EC 3.1.3.48 (Protein Tyrosine Phosphatase, Non-Receptor Type 12)
SB  - IM
MH  - Alleles
MH  - Carcinoma, Hepatocellular/*etiology
MH  - Case-Control Studies
MH  - Disease Susceptibility
MH  - *Gene Expression
MH  - Genotype
MH  - Hepatitis B/complications/*genetics/*virology
MH  - Hepatitis B virus/*genetics
MH  - Host-Pathogen Interactions/genetics
MH  - Humans
MH  - Liver Neoplasms/*etiology
MH  - *Mutation
MH  - Odds Ratio
MH  - Polymorphism, Single Nucleotide
MH  - Protein Tyrosine Phosphatase, Non-Receptor Type 12/*genetics
MH  - *Quantitative Trait Loci
PMC - PMC4944896
OTO - NOTNLM
OT  - HBV mutations
OT  - HCC
OT  - PTPN12
OT  - eQTL
OT  - interaction
OT  - susceptibility
EDAT- 2016/04/15 06:00
MHDA- 2017/11/29 06:00
PMCR- 2016/04/14
CRDT- 2016/04/15 06:00
PHST- 2015/11/27 00:00 [received]
PHST- 2016/02/29 00:00 [revised]
PHST- 2016/03/01 00:00 [accepted]
PHST- 2016/04/15 06:00 [entrez]
PHST- 2016/04/15 06:00 [pubmed]
PHST- 2017/11/29 06:00 [medline]
PHST- 2016/04/14 00:00 [pmc-release]
AID - CAM4712 [pii]
AID - 10.1002/cam4.712 [doi]
PST - ppublish
SO  - Cancer Med. 2016 Jul;5(7):1687-93. doi: 10.1002/cam4.712. Epub 2016 Apr 14.